Download PDF
Thromb Haemost 2012; 108(01): 6-8
DOI: 10.1160/TH12-05-0311
Invited Editorial Focus
Schattauer GmbH

Measurements of thromboxane production and their clinical significance in coronary heart disease

Giulia Renda
1   Institute of Cardiology and Center of Excellence on Aging, “G. d’Annunzio” University, Chieti, Italy
,
Raffaele De Caterina
1   Institute of Cardiology and Center of Excellence on Aging, “G. d’Annunzio” University, Chieti, Italy
2   Fondazione “G. Monasterio”, Pisa, Italy
› Author Affiliations
Further Information

Publication History

Received: 13 May 2012

Accepted: 19 May 2012

Publication Date:
22 November 2017 (online)

    Permissions and Reprints

 

 

  • References

  • 1 Kuliczkowski W, Witkowski A, Polonski L. et al. In-terindividual variability in the response to oral antiplatelet drugs: a position paper of the Working Group on antiplatelet drugs resistance appointed by the Section of Cardiovascular Interventions of the Polish Cardiac Society, endorsed by the Working Group on Thrombosis of the European Society of Cardiology. Eur Heart J 2009; 30: 426-435.
    PubMedGoogle Scholar
  • 2 Sibbing D, Byrne RA, Bernlochner I, Kastrati A. High platelet reactivity and clinical outcome - fact and fiction. Thromb Haemost 2011; 106: 191-202.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 3 Samuelsson B, Goldyne M, Granstrom E, Hamberg M, Hammarstrom S, Malmsten C. Prostaglandins and thromboxanes. Annu Rev Biochem 1978; 47: 997-1029.
    CrossrefPubMedGoogle Scholar
  • 4 Hamberg M, Svensson J, Samuelsson B. Thromboxanes: a new group of biologically active compounds derived from prostaglandin endoperoxides. Proc Natl Acad Sci USA 1975; 72: 2994-2998.
    CrossrefPubMedGoogle Scholar
  • 5 Patrono C. Biosynthesis and pharmacological modulation of thromboxane in humans. Circulation 1990; 81: I12-15 discussion I22-23.
    PubMedGoogle Scholar
  • 6 Patrono C, Ciabattoni G, Pugliese F. et al. Estimated rate of thromboxane secretion into the circulation of normal humans. J Clin Invest 1986; 77: 590-594.
    CrossrefPubMedGoogle Scholar
  • 7 Catella F, Healy D, Lawson JA. et al. 11-Dehydrothromboxane B2: a quantitative index of thromboxane A2 formation in the human circulation. Proc Natl Acad Sci USA 1986; 83: 5861-5865.
    CrossrefPubMedGoogle Scholar
  • 8 Ciabattoni G, Pugliese F, Davi G. et al. Fractional conversion of thromboxane B2 to urinary 11-dehydrothromboxane B2 in man. Biochim Biophys Acta 1989; 992: 66-70.
    CrossrefPubMedGoogle Scholar
  • 9 Cattaneo M. Laboratory detection of 'aspirin resistance': what test should we use (if any)?. Eur Heart J 2007; 28: 1673-1675.
    CrossrefPubMedGoogle Scholar
  • 10 FitzGerald GA, Healy C, Daugherty J. Thromboxane A2 biosynthesis in human disease. Fed Proc 1987; 46: 154-158.
    PubMedGoogle Scholar
  • 11 Davi G, Patrono C. Platelet activation and atherothrombosis. N Engl J Med 2007; 357: 2482-2494.
    CrossrefPubMedGoogle Scholar
  • 12 Eikelboom JW, Hirsh J, Weitz JI. et al. Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation 2002; 105: 1650-1655.
    CrossrefPubMedGoogle Scholar
  • 13 Santilli F, Romano M, Recchiuti A. et al. Circulating endothelial progenitor cells and residual in vivo thromboxane biosynthesis in low-dose aspirintreated polycythemia vera patients. Blood 2008; 112: 1085-1090.
    CrossrefPubMedGoogle Scholar
  • 14 Rocca B, Secchiero P, Ciabattoni G. et al. Cyclooxygenase-2 expression is induced during human megakaryopoiesis and characterizes newly formed platelets. Proc Natl Acad Sci U S A 2002; 99: 7634-9.
    CrossrefPubMedGoogle Scholar
  • 15 Henry P, Vermillet A, Boval B, Guyetand C, Petroni T, Dillinger JG, Sideris G, Sollier CB, Drouet L. 24-hour time-dependent aspirin efficacy in patients with stable coronary artery disease. Thromb Haemost 2011; 105: 336-344.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 16 O'Donnell CJ, Larson MG, Feng D. et al. Genetic and environmental contributions to platelet aggregation: the Framingham heart study. Circulation 2001; 103: 3051-3056.
    CrossrefPubMedGoogle Scholar
  • 17 Feher G, Feher A, Pusch G. et al. The genetics of antiplatelet drug resistance. Clin Genet 2009; 75: 1-18.
    CrossrefPubMedGoogle Scholar
  • 18 Catella-Lawson F, Reilly MP, Kapoor SC. et al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med 2001; 345: 1809-1817.
    CrossrefPubMedGoogle Scholar
  • 19 Renda G, Tacconelli S, Capone ML. et al. Celecoxib, ibuprofen, and the antiplatelet effect of aspirin in patients with osteoarthritis and ischemic heart disease. Clin Pharmacol Ther 2006; 80: 264-274.
    CrossrefPubMedGoogle Scholar
  • 20 Curtis JP, Krumholz HM. The case for an adverse interaction between aspirin and non-steroidal anti-inflammatory drugs: is it time to believe the hype?. J Am Coll Cardiol 2004; 43: 991-993.
    CrossrefPubMedGoogle Scholar
  • 21 Niccoli G, Giubilato S, Leo A. et al. Predictors of thromboxane levels in patients with Non-ST Elevation Acute Coronary Syndromes on chronic aspirin therapy. Thromb Haemost 2012; 108: 133-139.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 22 Niccoli G, Giubilato S, Russo E. et al. Plasma levels of thromboxane A2 on admission are associated with no-reflow after primary percutaneous coronary intervention. Eur Heart J 2008; 29: 1843-1850.
    CrossrefPubMedGoogle Scholar
  • 23 Spectre G, Arnetz L, Ostenson CG. et al. Twice daily dosing of aspirin improves platelet inhibition in whole blood in patients with type 2 diabetes mellitus and micro- or macrovascular complications. Thromb Haemost 2011; 106: 491-499.
    Article in Thieme ConnectPubMedGoogle Scholar